The goal of this clinical research study is to learn if Tasigna® (nilotinib) can cause tumor
cells to shrink and/or die in patients with GIST who are scheduled for surgery or may be
eligible for surgery. The safety of this drug will be studied. Researchers also want to use
imaging scans to study the changes in tumor size that may be caused by using nilotinib.